Rankings
▼
Calendar
RCUS Q3 2023 Earnings — Arcus Biosciences, Inc. Revenue & Financial Results | Market Cap Arena
RCUS
Arcus Biosciences, Inc.
$2B
Q3 2023 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$32M
-3.0% YoY
Gross Profit
$32M
100.0% margin
Operating Income
-$80M
-250.0% margin
Net Income
-$71M
-221.9% margin
EPS (Diluted)
$-0.95
QoQ Revenue Growth
+10.3%
Cash Flow
Operating Cash Flow
-$63M
Free Cash Flow
-$73M
Stock-Based Comp.
$18M
Balance Sheet
Total Assets
$1.2B
Total Liabilities
$671M
Stockholders' Equity
$520M
Cash & Equivalents
$184M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$32M
$33M
-3.0%
Gross Profit
$32M
$33M
-3.0%
Operating Income
-$80M
-$70M
-14.3%
Net Income
-$71M
-$65M
-9.2%
Revenue Segments
License and Development Services Revenue
$22M
69%
Other Collaboration Revenue
$10M
31%
← FY 2023
All Quarters
Q4 2023 →